ACER-001 Study Initiated for MCADD in Pediatric and Adult Patients
A clinical trial is underway to evaluate sodium phenylbutyrate (ACER-001) for treating MCADD in patients aged 4 and older.
Therapeutic Area
Therapeutic area intelligence for Medium Chain Acyl-CoA Dehydrogenase Deficiency with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.